PROCEPT BioRobotics Corporation
General ticker "PRCT" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $1.6B (TTM average)
PROCEPT BioRobotics Corporation does not follow the US Stock Market performance with the rate: -27.8%.
Estimated limits based on current volatility of 3.4%: low 17.71$, high 18.95$
Factors to consider:
- Total employees count: 888 (+17.5%) as of 2025
- US accounted for 35.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Insufficient capital, Supply chain disruptions, Manufacturing capacity, Customer concentration
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [17.96$, 41.53$]
- 2026-12-31 to 2027-12-31 estimated range: [15.07$, 34.77$]
Financial Metrics affecting the PRCT estimates:
- Negative: with PPE of -19.0 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: 0.47 < Industry inventory ratio change (median), % of 0.70
- Negative: -3.92 < Inventory ratio change, % of -1.43
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: 0.07 < Interest expense per share per price, % of 0.20
- Negative: 69.38 < Shareholder equity ratio, % of 72.01 <= 81.92
Short-term PRCT quotes
Long-term PRCT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $136.19MM | $224.50MM | $308.05MM |
| Operating Expenses | $245.36MM | $321.11MM | $411.91MM |
| Operating Income | $-109.17MM | $-96.61MM | $-103.86MM |
| Non-Operating Income | $3.27MM | $5.20MM | $8.48MM |
| Interest Expense | $4.00MM | $4.18MM | $3.59MM |
| R&D Expense | $48.45MM | $62.30MM | $71.28MM |
| Income(Loss) | $-105.90MM | $-91.41MM | $-95.38MM |
| Taxes | $0.00MM | $0.00MM | $0.19MM |
| Net Income(Loss)* | $-105.90MM | $-91.41MM | $-95.57MM |
| Stockholders Equity | $280.75MM | $402.22MM | $365.87MM |
| Inventory | $39.76MM | $56.17MM | $70.69MM |
| Assets | $404.72MM | $534.02MM | $508.08MM |
| Operating Cash Flow | $-108.00MM | $-99.21MM | $-48.98MM |
| Capital expenditure | $25.21MM | $4.41MM | $9.36MM |
| Investing Cash Flow | $-25.21MM | $-4.41MM | $-9.36MM |
| Financing Cash Flow | $167.79MM | $180.12MM | $11.19MM |
| Earnings Per Share** | $-2.24 | $-1.75 | $-1.72 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.